Ocular Therapeutix, Inc. (OCUL)
Nasdaq · Healthcare · Biotechnology
$7.25+4.17%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.6B
- 52-week range
- $6.23 – $16.44
- 52-week change
- −39.58%
- EPS (trailing)
- −$1.40
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $52.0M (−18.47%)
- Net income
- −$266M
- Operating margin
- −519.8%
- Diluted EPS
- −$1.42
- Free cash flow
- −$217M
From the company’s annual report on SEC EDGAR.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Headquarters: Bedford, United States · 325 employees · ocutx.com